Antifungal Guidelines

Guideline for Primary Antifungal Prophylaxis for Pediatric Patients with Cancer or Hematopoietic Stem Cell Transplant Recipients (Completed; February 2014)

A condensed version of the guideline has been published in Pediatric Blood and Cancer:
Science M, Robinson PD, MacDonald T, Rassekh, SR, Dupuis LL and Sung L. Guideline for Primary Antifungal Prophylaxis for Pediatric Patients with Cancer or Hematopoietic Stem Cell Transplant Recipients. Pediatric Blood and Cancer (2014) 61:393-400 

APPHON has adapted for local use the C17 guideline for Primary Antifungal Prophylaxis for Pediatric Patients with Cancer or Hematopoietic Stem Cell Transplant recipients.

**The single change that has been made by APPHON in consultation with the IWK & Janeway Infectious Disease Specialists is not recommending the use of Posaconazole for primary prophylaxis at this time due to the low rates of resistance to fluconazole in the Maritimes. In all areas of the document where posaconazole is recommended APPHON is recommending fluconazole (6-12 mg/kg/day) IV/PO once daily (maximum 400 mg/day).** 

 

Link to the 2014 Guideline for Primary Antifungal Prophylaxis for Pediatric Patients with Cancer of Hematopoietic Stem Cell Transplant Recipients